Vincristine therapy for severe and refractory immune thrombocytopenia following COVID-19 vaccination.

Saito, Kei; Ichikawa, Satoshi; Hatta, Shunsuke; Katsuoka, Yuna; Harigae, Hideo; Izumi, Tohru

Saito, Kei; Ichikawa, Satoshi; Hatta, Shunsuke; Katsuoka, Yuna; Harigae, Hideo; Izumi, Tohru.

Saito K; Department of Hematology, National Hospital Organization Sendai Medical Center, Sendai, Japan.
Ichikawa S; Department of Hematology, Tohoku University Hospital, Sendai, Japan.
Hatta S; Department of Hematology, Tohoku University Hospital, Sendai, Japan. satoshi.ichikawa.b4@tohoku.ac.jp.
Katsuoka Y; Department of Hematology, National Hospital Organization Sendai Medical Center, Sendai, Japan.
Harigae H; Department of Hematology, Tohoku University Hospital, Sendai, Japan.
Izumi T; Department of Hematology, National Hospital Organization Sendai Medical Center, Sendai, Japan.

Ann Hematol ; 101(4): 885-887, 2022 04.

Article in English | MEDLINE | ID: covidwho-1446135

Subject(s)

COVID-19; Purpura, Thrombocytopenic, Idiopathic; COVID-19/prevention & control; COVID-19 Vaccines/adverse effects; Humans; Purpura, Thrombocytopenic, Idiopathic/drug therapy; Purpura, Thrombocytopenic, Idiopathic/etiology; SARS-CoV-2; Vaccination; Vincristine

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Purpura, Thrombocytopenic, Idiopathic / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Ann Hematol Journal subject: Hematology Year: 2022 Document Type: Article Affiliation country: S00277-021-04666-x

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google